1. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**
   Miller et.al; BMJ 2014

2. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**
   Cheng et.al; JAMA 2014

3. **Age-Adjusted D-Dimer Cutoff Levels to Rule out Pulmonary Embolism. The ADJUST-PE Study**
   Righini, Van Es et. Al.; JAMA 2014

4. **Changes in Mortality after Massachusetts Health Care Reform**
   Sommers, Long et. Al; Annals of Internal Medicine; May 6th, 2014

   Rohde et.al; JAMA 2014

6. **Aspirin in Patients Undergoing Noncardiac Surgery**
   Devereaux et al; NEJM April 2014

7. **Albumin Replacement in Patients with Severe Sepsis or Septic Shock**
   Caironi et al; NEJM April 2014

8. **A Randomized Trial of Protocol-Based Care for Early Septic Shock**
   The ProCESS Investigators; NEJM March 18th, 2014

9. **High versus Low Blood-Pressure Target in Patients with Septic Shock**
   Asfar et.al; NEJM March 18th, 2014

10. **Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock**
    Rivers et.al; NEJM Nov 8th, 2001

11. **Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome.**
    Kazi MD, et. Al. Annals of Internal Medicine, Feb 2014
12. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation (The CURE Trial). NEJM 2001


14. Upper Airway Stimulation for Obstructive Sleep Apnea. Strollo, Soose, Maurer et al. NEJM 2014


16. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Bouadma et al; Lancet, 2010

17. Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes. Tobias et al; NEJM Jan 16th, 2014

18. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA December 2013


21. Effects of Vitamin D supplements on bone mineral density: A systematic review and meta-analysis


23. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. REENAL Study (NEJM) 2001

25. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. REENAL Study (NEJM) 2001

26. Aggressive Fluid and Sodium Restriction in Acute Decompensated Heart Failure JAMA, June 2013


28. Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The REDUCE Randomized Clinical Trial. JAMA, May 2013


30. Therapies for Active Rheumatoid Arthritis after Methotrexate Failure O’Dell et al; NEJM July 25, 2013

31. Diagnostic Blood Loss From Phlebotomy and Hospital-Acquired Anemia During Acute Myocardial Infarction Salisbury et al; Arch Intern Med; October 10, 2011

32. “Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women” BMJ

33. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women” (results from the Women’s Health Initiative) JAMA

34. “Associations Between Reduced Hospital Length of Stay and 30 Day Readmission Rate & Mortality” Annals of Internal Medicine
35. **Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality**  
The National Institutes of Health

36. **Blood Pressure and Mortality in U.S. Veterans with Chronic Kidney Disease**  
Annals of Internal Medicine

37. **Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes**  
The New England Journal of Medicine

38. **Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival**  
JAMA, December 21, 2011

39. **Screening for Lung Cancer with Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation**  
Annals of Internal Medicine

40. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**  
Miller et.al; BMJ 2014

41. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**  
Cheng et.al; JAMA 2014

42. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**  
Miller et.al; BMJ 2014

43. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**  
Cheng et.al; JAMA 2014

44. **Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD**  
Criner et. al  
NEJM June 14, 2014

45. **Atrial Fibrillation in Patients with Cryptogenic Stroke**  
Gladstone et. al
46. Once weekly Dalbucacin versus conventional therapy for skin infection
   Boucher, et. al
   NEJM June 5th, 2014

47. Pregnancy Incidence and Outcomes Among Women Receiving Pre-exposure Prophylaxis for HIV Prevention: A Randomized Clinical Trial
   Nelly R. Mugo, MBChB, MPH1,2,3; et. al
   http://jama.jamanetwork.com/article.aspx?articleid=1889140&resultClick=3

48. Telecare Collaborative Management of Chronic Pain in Primary Care: A Randomized Clinical Trial
   Kurt Kroenke, MD1,2,3; Erin E. Krebs, MD4,5; Jingwei Wu, MS6; Zhangsheng Yu, PhD6; Neale R. Chumbler, PhD7; Matthew J. Bair, MD1,2,3
   http://jama.jamanetwork.com/article.aspx?articleid=1887761&resultClick=3

49. Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation: A Randomized Clinical Trial
   Coenraad F. N. Koegelenberg, MD, PhD1; et.al

50. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
   Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., et.al

51. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY Trial)
   Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., et.al and the RE-LY Steering Committee and Investigators

52. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results from Two Multinational, Randomized, Controlled Trials
Stuart Johnson, Thomas Louie, et. al for the Polymer Alternative for CDI Treatment (PACT) investigators

Clinical Infectious Diseases; July 2014

53. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Michiel Coppens, John W. Eikelboom et. Al
European Heart Journal, September 2012

54. The Risk of Melanoma in Airline Pilots and Cabin Crew
Martina Sanlorenzo, MD et.al
JAMA Dermatol. Published online September 03, 2014

55. Cardiovascular Risk and Events in 17 Low, Middle and High-Income Countries
S. Yusuf et.al
NEJM, August 28, 2014

56. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
J.J. McMurray et. al
NEJM, September 11th, 2014

57. The Risk of Melanoma in Airline Pilots and Cabin Crew
Martina Sanlorenzo, MD et. al
JAMA Dermatol. Published online September 3, 214

58. Cardiovascular Risk and Events in 17 Low, Middle and High-Income Countries
S. Yusuf et. al
NEJM, August 28, 2014

59. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
J.J. McMurray et. al
NEJM, September 11, 2014

60. A Controlled Trial of Renal Denervation for Resistant Hypertension
Deepak L. Bhatt, M.D., M.P.H., David E. Kandzari, M.D et.al for the SYMPLICITY HTN-3 Investigators
NEJM, March 29th, 2014
61. **Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes who do not have Adequate Glycemic Control With Metformin Plus Sulfonylurea**  
   G. Schernthaner, J. Gross et.al  
   Diabetes Care, April 5, 2013

62. **Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes**  
   Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., et.al for the STAMPEDE Investigators  
   NEJM, March 31, 2014

63. **Multitarget Stool DNA Testing for Colorectal-Cancer Screening**  
   Thomas F. Imperiale, et. Al  
   NEJM April 3rd, 2014

64. **A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis**  
   B. Joseph Elmunzer, et. al  
   NEJM April 12, 2012

65. **Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis**  
   Kris V. Kowdley, et. al  
   NEJM May 15, 2014

66. **Goal-Directed Resuscitation for Patients with Early Septic Shock**  
   The ARISE Investigators and the ANZICS Clinical Trials Group*  
   October 1st, 2014

67. **Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease**  
   Bernard De Bruyne, M.D., Ph.D. et.al  
   NEJM September 2014

68. **Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients**  
   The HPS2-THRIVE Collaborative Group*  
   NEJM July 2014

69. **Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 years or Older with Atherosclerotic Risk Factors**  
   Y. Ikeda et. al, JAMA, November 17, 2014  
70. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
J. Cuzick et.al, Lancet, December 2014
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/abstract

71. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
P. Ridker et.al, NEJM, March 200

72. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop
Roger Chou, MD et. Al
Annals of Internal Medicine, Feb 17th, 2015

73. Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines
Andrew E. Moran, M.D., M.P.H., Michelle C. Odden, Ph.D., et.al

74. Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke
Gino Gialdini, MD1; Katherine Nearing, MD2; et.al
JAMA, August 13th, 2015

75. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection
Emily G. McDonald, MD et.al
JAMA, March 2 2015

76. Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction
Anne-Marie Schjerning Olsen, MD et.al
JAMA Feb 24, 2015

77. Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis
Saurav Chatterjee, MD et.al
JAMA, June 18 2014

78. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults
79. **Trial of Early, Goal-Directed Resuscitation for Septic Shock**  
   Paul R. Mouncey, M.Sc., Tiffany M. Osborn, M.D et.al  
   NEJM, April 2\(^{nd}\), 2015

80. **Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease**  
   Pamela S. Douglas, M.D., et.al  
   NEJM, April 2\(^{nd}\), 2015

81. **Prednisolone or Pentoxifylline for Alcoholic Hepatitis**  
   Mark R. Thursz, M.D et.al  
   NEJM, April 23rd, 2015

82. **Association of Early Imaging for Back Pain with Clinical Outcomes in Older Adults**  
   Jeffrey Jarvik, MD et.al  
   JAMA March 17, 2015

83. **Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials**  
   Gustavo C Machado, PhD, et.al  
   BMJ, March 2015

84. **Clindamycin versus Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Infections**  
   Loren G. Miller, M.D., M.P.H., et.al  
   NEJM March 19, 2015

85. **Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.**  
   Walters JA et.al  
   Cochrane Database Syst Rev. 2014.

86. **Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial.**  
   J Am Coll Cardiol. 2014
87. **Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.**
   Mismetti P et. al

88. **Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures**
   Nathan P. Clark, PharmD1,2; Daniel M. Witt, PharmD1,3; et.al
   *JAMA Intern Med.* Published online May 26, 2015

89. **Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial**
   Louis Bernard, Aurélien Dinh, Idir Ghout, David Simo, Valerie Zeller, et.al on behalf of the Duration of Treatment for Spondylodiscitis (DTS) study group*

90. **A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management**
   Xavier Pi-Sunyer, M.D., Arne Astrup, M.D., D.M.Sc., Ken Fujioka, M.D., Frank Greenway, M.D., et.al for the SCALE Obesity and Prediabetes NN8022-1839 Study Group*
   *NEJM*, July 2, 2015

91. **Effects of intensive blood-pressure control in type 2 diabetes mellitus**
   Cushman WC, Evans GW, Byington RP, et al.


93. **Telmisartan, ramipril, or both in patients at high risk for vascular events.**
   Yusuf S, Teo KK, Pogue J, et al.
94. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
   Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., et.al

95. Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer
   Jane C. Weeks, M.D, et. al

96. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
   Holly G. Prigerson, PhD et. Al

97. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial
   Francis Couturaud, MD, PhD; Olivier Sanchez, MD, PhD et.al
   JAMA July 7 2015

98. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
   The INSIGHT START Study Group
   NEJM August 27, 2015

99. Screening for Occult Cancer in Unprovoked Venous Thromboembolism
   Marc Carrier, M.D., Alejandro Lazo-Langner, M.D., et.al
   NEJM August 20, 2015

100. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
    James D. Douketis, M.D., Alex C. Spyropoulos MD, et.al
    NEJM August 27, 2015

101. Terlipressin Plus Albumin Versus Midodrine and Octreotide Plus Albumin in the Treatment of Hepatorenal Syndrome: A Randomized Trial
    Marta Cavallin, et. Al
    Hepatology, August 2015

102. Intravascular Complications of Central Venous Catheterization by Insertion Site
    Jean-Jacques Parienti, et. al
    NEJM, September 25, 2015
103. Effect Of Intravenous Albumin On Renal Impairment and Mortality in Patients With Cirrhosis And Spontaneous Bacterial Peritonitis
    Pau Sort, et.al
    NEJM, 1999

104. Calcium intake and risk of fracture: systematic review.
    BMJ. 2015 Sep 29

105. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    N Engl J Med. 2015 Sep 17

106. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2
    Williams B, MacDonald TM, Morant S, et al.
    Lancet. 2015 Sep 18

107. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain
    Benjamin W. Friedman, MD et.al
    JAMA October 20, 2015

    Jorgensen ME, Hlatky MA, Kober L, et al.
    JAMA, October 5, 2015

109. A Randomized Trial of Intensive versus Standard Blood-Pressure Control
    The SPRINT Research Group
    NEJM, November 26, 2015

110. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease
    Steven P. Sedlis, M.D. et.al
    NEJM, November 12, 2015

    BMJ Nov 2015
112. **Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.**
van den Ham HA, Klungel OH, Singer DE, et al.
J Am Coll Cardiol. 2015 Oct

113. **A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation**
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators

114. **Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)**
Umpierrez GE¹, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R

115. **Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)**
UK Prospective Diabetes Study (UKPDS) Group.
Lancet. 1998 Sep 12

116. **Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes**
Rodney A. Hayward, M.D., Peter D. Reaven, M.D., et.al for the VADT Investigators
NEJM June 4, 2015

117. **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**
The INSIGHT START Study Group
NEJM August 27, 2015

118. **Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial**
Lindsey R. Baden, MD; Etienne Karita, MD et.al
Annals of Internal Medicine Feb 2016
119. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
   David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
   NEJM June 26 2014

120. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
   The INSIGHT START Study Group
   NEJM August 27, 2015

121. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial
   Lindsey R. Baden, MD; Etienne Karita, MD et.al
   Annals of Internal Medicine Feb 2016

122. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
   David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
   NEJM June 26 2014

123. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
   The INSIGHT START Study Group
   NEJM August 27, 2015

124. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial
   Lindsey R. Baden, MD; Etienne Karita, MD et.al
   Annals of Internal Medicine Feb 2016

125. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
   David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
   NEJM June 26 2014

126. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score
   MAJ David C. Hostler et.al
   Chest 2015

127. Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess
   David A. Talan et.al
   NEJM March 3, 2016
128. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**  
Rozalina G McCoy et.al  
BMJ 2015

129. **Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score**  
MAJ David C. Hostler et.al  
Chest 2015

130. **Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess**  
David A. Talan et.al  
NEJM March 3, 2016

131. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**  
Rozalina G McCoy et.al  
BMJ 2015

132. **Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score**  
MAJ David C. Hostler et.al  
Chest 2015

133. **Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess**  
David A. Talan et.al  
NEJM March 3, 2016

134. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**  
Rozalina G McCoy et.al  
BMJ 2015

135. **Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation (SPINAF)**  
Michael D. Ezekowitz, M.D., Ph.D., Samuel L. Bridgers, M.D. et.al  
NEJM 1992
136. **Rivaroxaban versus Warfarin in Non-Valvular Atrial Fibrillation (ROCKET AF)**  
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D. et.al  
NEJM Sept 8, 2011

137. **Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation (SPINAF)**  
Michael D. Ezekowitz, M.D., Ph.D., Samuel L. Bridgers, M.D. et.al  
NEJM 1992

138. **Rivaroxaban versus Warfarin in Non-Valvular Atrial Fibrillation (ROCKET AF)**  
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D. et.al  
NEJM Sept 8, 2011

139. **Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy**  
Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*  
NEJM April 21, 2016

140. **Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease**  
Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators  
NEJM April 2, 2016

141. **Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes**  
Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT Investigators  
NEJM June 18, 2015

142. **Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy**  
Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*  
NEJM April 21, 2016

143. **Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease**
144. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
   Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT
   Investigators
   NEJM June 18, 2015

145. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy
   Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*
   NEJM April 21, 2016

146. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
   Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators
   NEJM April 2, 2016

147. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
   Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT
   Investigators
   NEJM June 18, 2015

148. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
   Mervyn Singer, MD, FRCPl; Clifford S. Deutschman, MD, MS et. Al
   JAMA Feb 23 2016

149. Nutritional Support and Outcomes in Malnourished Medical Inpatients: A Systematic Review and Meta-analysis
   Bally MR1, Blaser Yildirim PZ2, et. Al
   JAMA Jan 2016
150. **Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease**
   Eva M. Lonn, M.D., Jackie Bosch, Ph.D et.al
   NEJM April 2016

151. **Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients**
   Martin B. Leon, M.D., Craig R. Smith
   NEJM April 2016

152. **The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)**
   Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS et. Al
   JAMA Feb 23 2016

153. **Nutritional Support and Outcomes in Malnourished Medical Inpatients: A Systematic Review and Meta-analysis.**
   Bally MR1, Blaser Yildirim PZ2, et. Al
   JAMA Jan 2016

154. **Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease**
   Eva M. Lonn, M.D., Jackie Bosch, Ph.D et.al
   NEJM April 2016

155. **Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients**
   Martin B. Leon, M.D., Craig R. Smith
   NEJM April 2016

156. **Invasive versus conservative strategy in patients aged 80 years or older with NSTEMI or unstable angina pectoris (After Eighty study)**
   Nicolai Tegn, Michael Abdelnoor, et.al
   Jan 12, 2016 (Lancet)

157. **Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack**
158. *Invasive versus conservative strategy in patients aged 80 years or older with NSTEMI or unstable angina pectoris (After Eighty study)*

Nicolai Tegn, Michael Abdelnoor, et.al
Jan 12, 2016 (Lancet)

159. *Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack*

S. Claiborne Johnston, M.D., Ph.D., Pierre Amarenco, M.D., et. Al for the SOCRATES Steering Committee and Investigators
May 10, 2016 (NEJM)